Clinical Trial Update: Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating gefitinib combined with chemotherapy or anti-angiogenesis therapy in non-small-cell lung cancer patients with BIM deletion o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN